Search PubMed⌕ Search

Biomedical subjects

L Conti

Publications and source records attributed to L Conti.

171 records · Page 10Linked to original sources

[Multicenter psychopharmacologic research and the data bank].

The indications and the characteristics of the multicenter clinical trials are considered and the BLIPS/BDP system is showed in detail as developed at the Institute of Clinical Psychiatry of the University of Pisa within the cooperation with the National Institute of Mental Health (NIMH-USA) at the Center for Clinical Psychopharmacology Data Documentation (CCPDD). The characteristics of the BLIPS/BDP system in the storage, retrieval and documentation of data derived from clinical trials on psychotropic drugs are reported. Finally, examples are given of the large number of possible utilizations of the BLIPS/BDP Data Bank documenting its flexibility and versatility and the extent of its possibilities.

Clinical Trials as Topic↗

[An extreme case of Lobstein's osteopsathyrosis: problems of surgical correction].

Those surgeons who have had experience of Sofield's treatment in case of osteogenesis inperfecta would be unanimous in agreeing that this method offers great advantages to these unfortunate children. Although the technic is exact and the results often cancelled out by the growth so that the re-operation is indicated, nevertheless the long fracture-free period gained and the control of deformity confer very worth-while benefits. A case of O.I. is reported; the subject presented fracture sequaele in the lower limbs and bone alterations of extreme seriousness. Sofield's treatment was not possible in the rodding time; the Authors describe a modified treatment which has proved useful in practice. Notes on the specific features, course and treatment are presented; a particular attention is paid to its genetic and etiopathogenetic aspects.

Adolescent↗

Socioeconomic differences among people with AIDS: results from a Multistate Surveillance Project.

To characterize the socioeconomic status of persons with acquired immunodeficiency syndrome (AIDS), 11 U.S. state and city health departments interviewed 2,898 persons > or = 18 years of age reported with AIDS between June 1, 1990, and January 31, 1993. Among men who have sex with men, white men reported the lowest percentage (9%), and Central/South American (50%) and Mexican men (40%) reported the highest percentages not completing 12 years of school. Among intravenous drug users (IDUs), 35% of white men, 64% of black men, 67% of Puerto Rican men, 29% of white women, and 63% of black women had not completed 12 years of school. Overall, 77% of the men and 90% of the women were unemployed; we also found racial/ethnic differences by employment but to a lesser degree than differences in education. Among women, but not among men, differences in household income by race and ethnicity were marked; 76% of white and 91% of black female IDUs reported a household income of $10,000. Human immunodeficiency virus (HIV) prevention programs must be targeted toward the educational level of the populations served, and HIV services must adapt to the financial circumstances of their clientele.

Acquired Immunodeficiency Syndrome↗

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.

The impact of prognostic markers on disease-free and overall survival reflects their relative role in tumour biology. Breast cancer and colon carcinoma can be taken as examples to demonstrate the clinical and biological relevance of 'new markers' of neoplastic disease. In breast cancer, receptor-bound urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 seem to play an important role in the dissolution of the surrounding tissue and the formation of tumour stroma. These processes are prerequisites for invasion and metastasis. The study of 'classical' and 'new' prognostic factors showed that uPA and PAI-1 content of breast cancer tissue are strong and independent prognostic factors. Also in colorectal cancer the prognostic relevance of plasminogen activators and inhibitors was analysed. In particular, low tissue plasminogen activator (tPA) levels, as antigen or as activity, high uPA: tPA antigen ratio in corresponding normal mucosa, high levels of uPA-related antigen and activity and of PAI-2 antigen in neoplastic tissue, and high uPA (neoplastic mucosa): tPA (normal mucosa) ratio, were all parameters associated with a poor overall survival. In conclusion, all these observations show the clinical importance of plasminogen activators and inhibitors at tissue levels with respect to cancer development and survival of patients affected by breast carcinoma or colorectal neoplasia. These new prognostic markers will also permit a better patient selection for a possible adjuvant treatment.

Breast Neoplasms↗

Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors.

BACKGROUND: Recent demonstrations that the JAK/STAT and ShcA signalling proteins are abundant in the developing CNS at the stage of maximal cell proliferation prompted us to determine whether these proteins were expressed in various human brain tumors. MATERIALS AND METHODS: Using Western blot assay, we analyzed specimens from control peritumoral brain tissue, medulloblastomas, ependimomas, astrocytomas, anaplastic astrocytomas and glioblastomas. RESULTS: Our analyses revealed that Jak1 and Stat3 were consistently more elevated in low grade gliomas (LG) (tumors characterized by a more pronounced glial phenotype) as compared to high grade gliomas (HG) (less differentiated glial tumors). The other STAT proteins were equally expressed, while Stat1 was slightly higher in LG gliomas. Among the other tumors analyzed, medulloblastoma contained the highest level of Jak1 and Stat3, while ependymoma showed elevated levels of ShcA proteins. CONCLUSIONS: These differences may reflect differences in the biological characteristics of the various tumors and may provide insight for further mechanistic studies to investigate the importance of particular signal transduction pathways in CNS tumors.

Acute-Phase Proteins↗